Die Grafik zeigt die prognostizierten Quartalsgewinne (Bereinigter Gewinn pro Aktie, EPS) und die tatsächlich erzielten Gewinne (grün: Analystenschätzungen übertroffen, rot: Analystenschätzungen verfehlt) für den ausgewählten Zeitraum.
Umsatz (USD)
Schätzung
Umsatz
Die Grafik zeigt die prognostizierten Quartalsumsätze und die tatsächlich erzielten Umsätze (grün: Analystenschätzungen übertroffen, rot: Analystenschätzungen verfehlt) für den ausgewählten Zeitraum.
Güte der Analystenschätzungen – EPS (aktueller Zeitraum)
Quartal / Datum
EPS (USD)
Schätzung (USD)
Abweichung
Quartal / Datum
Umsatz (Mio USD)
Schätzung (Mio USD)
Abweichung
Revisionen der Gewinnschätzungen
EPS-Schätzungen für die Geschäftsjahre
2026, 2027, 2028.
BETHLEHEM, Pa., May 06, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced its financial results for the three months ended March 31, 2026.
BETHLEHEM, Pa., April 22, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering first quarter 2026 financial results and certain business developments for 5 p.m. ET on May 6, 2026.
Enters into Cooperation Agreement with Altai Capital Board to Seek Shareholder Approval for Declassification at the 2026 Annual Meeting BETHLEHEM, Pa., April 16, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (“OraSure” and “OTI”) (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced the appointment of John D.
OraSure Technologies, Inc. (NASDAQ: OSUR - Get Free Report)'s share price crossed above its 200-day moving average during trading on Tuesday. The stock has a 200-day moving average of $2.77 and traded as high as $3.08. OraSure Technologies shares last traded at $3.06, with a volume of 304,439 shares traded. Wall Street Analyst Weigh In
Shares of OraSure Technologies, Inc. (NASDAQ: OSUR - Get Free Report) crossed above its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $2.78 and traded as high as $2.99. OraSure Technologies shares last traded at $2.92, with a volume of 402,952 shares. Analyst Ratings Changes Separately, Weiss Ratings
Company Has Demonstrated Momentum on Transformation Strategy with Significant Regulatory and Commercial Milestones Approaching in 2026 Highlights Extensive Engagement with Altai Altai Has Rejected All Settlement Proposals and Is Singularly Focused on Securing Board Representation for Its Founder to Force an Ill-Timed Sale Process BETHLEHEM, Pa., March 17, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (“OraSure” and the “Company”) (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today issued the following statement in response to Altai Capital's March 17, 2026, letter: OraSure's Board and management team are steadfast in our commitment to driving value and acting in the best interests of all shareholders through disciplined execution and rigorous oversight.
LOS ANGELES--(BUSINESS WIRE)--Altai Capital Management, L.P. ("Altai"), one of the largest shareholders and the beneficial owners of approximately 5% of the outstanding common stock of OraSure Technologies, Inc. (“OraSure” or the “Company”) (NASDAQ: OSUR), today announced that it has delivered a letter to the OraSure Board of Directors (the “Board”) outlining a five-pillar case for why change is necessary to preserve and deliver value for its investors. In the letter, Altai calls on the OraSure.
Activist investor Altai Capital Management called on OraSure Technologies to explore a sale, saying the medical device maker could fetch double its current share price, according to a letter seen by Reuters.